Market Overview

UPDATE: Jefferies Downgrades GlaxoSmithKline to Hold on Margin Expansion Visibility

Share:
Related GSK
7 Trends Drug Investors Should Know
Top 4 Large-Cap Stocks In The Drug Manufacturers Industry With The Highest ROE
7 Top Dividend Sector Dogs Fetch 24% To 50% April Upsides (Seeking Alpha)

Jefferies cut its rating on GlaxoSmithKline (NYSE: GSK) from Buy to Hold on reduced visibility to the company's margin expansion.

Jefferies commented, "Whilst we still see double digit CORE EPS growth for GlaxoSmithKline from 2013E-17E, visibility on margin expansion has been obscured by over-exposure to price pressure and transfer pricing in Europe. The shares have recovered well from their lows since the Q2'12 results and we take this opportunity to cut our rating to Hold from Buy given the limited upside."

GlaxoSmithKline closed at $46.84 on Friday.

Latest Ratings for GSK

DateFirmActionFromTo
Jan 2015New Street ResearchDowngrades
Jul 2014MainfirstDowngradesUnderperform
Apr 2014Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (GSK)

Around the Web, We're Loving...